NCT07114939View on ClinicalTrials.gov

FTT PET/CT in Pancreatic Neuroendocrine Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

September 30, 2027

Study Completion Date

September 30, 2027

Conditions
Neuroendocrine Carcinoma MetastaticPancreatic Tumors
Interventions
DRUG

[18F]FluorThanatrace

Intravenous injection of ≤ 12 mCi of \[18F\]FTT for whole-body PET CT dynamic imaging and subsequent static scan.

Trial Locations (1)

19104

RECRUITING

University of Pennsylvania, Perelman Center for Advanced Medicine, Philadelphia

All Listed Sponsors
collaborator

University of Pennsylvania

OTHER

lead

Abramson Cancer Center at Penn Medicine

OTHER

NCT07114939 - FTT PET/CT in Pancreatic Neuroendocrine Tumors | Biotech Hunter | Biotech Hunter